Back to search results

Diagnosing ATTR in Heart Failure with Preserved Ejection Fraction

This study aims to understand how often transthyretin amyloidosis (ATTR) causes a type of heart failure called Heart Failure with Preserved Ejection Fraction (HFpEF), where the heart pumps normally but doesn't relax properly. Researchers will use a diagnostic test called 99mTc-pyrophosphate Scintigraphy, a cardiac imaging technique, to look for ATTR in people with HFpEF. The main goal is to see how frequently ATTR is diagnosed using this scan. You may be able to join if you are 65 or older and have a confirmed diagnosis of HFpEF. The study hopes to identify ATTR earlier in heart failure patients so they can receive appropriate treatment. The current status of the study is unclear.

Study design
This is an interventional study with a planned enrollment of 515 participants. It is a single-center diagnostic study.
What's involved
You would have a single study visit where you would receive a 99mTc-pyrophosphate SPECT scan, provide blood and optional DNA samples, complete questionnaires, perform a 6-Minute Walk Test, and have an ECG and echocardiogram.
Compensation
Not stated in the trial record.
Follow-up
Your electronic health records will be reviewed for up to 5 years to track hospitalizations and survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05577819

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Recruiting
NAAges 65+InterventionalDiagnostic
Massachusetts General Hospital
~515 participants
Updated 2024-12-09 on ClinicalTrials.gov
What's tested:99mTc-pyrophosphate Scintigraphy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnosis of 99mTc-pyrophosphate scan positive ATTR
Measured over Day 1 (day of study visit)

Conditions

Transthyretin Amyloidosis
Heart Failure
Heart Failure, Diastolic
Amyloidosis

Explore related trials

ATTR AmyloidosisHeart failure with normal ejection fraction

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Hanna K Gaggin, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Abbie Macher, BS
[email protected]
617-643-6328
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a confirmed diagnosis of HFpEF.
Age ≥65 years old

Exclusion

End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
Negative 99mTc-pyrophosphate scan within a year
Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
Known diagnosis of amyloidosis
Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)

What this trial measures

  • Diagnosis of 99mTc-pyrophosphate scan positive ATTRDay 1 (day of study visit)

    A cardiac disease in which misfolded proteins aggregate into amyloid fibril and deposit interstitially, leading to diastolic dysfunction and heart failure